share_log

HC Wainwright & Co. Downgrades Acelyrin to Neutral, Lowers Price Target to $6

Benzinga ·  Aug 16 01:21  · Ratings

HC Wainwright & Co. analyst Emily Bodnar downgrades Acelyrin (NASDAQ:SLRN) from Buy to Neutral and lowers the price target from $18 to $6.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment